Brief: Longboard Pharmaceuticals Reports Full Year 2022 Financial Results And Key Corporate Initiatives

Longboard Pharmaceuticals

02/03/2023 21:28

March 2 (Reuters) - Longboard Pharmaceuticals Inc
 LBPH.O :
    * LONGBOARD PHARMACEUTICALS REPORTS FULL YEAR 2022 FINANCIAL
RESULTS AND KEY CORPORATE INITIATIVES
    * LONGBOARD PHARMACEUTICALS INC FY LOSS PER SHARE $2.56
    * LONGBOARD PHARMACEUTICALS INC - LP352 PHASE 1B/2A PACIFIC
STUDY
REMAINS ON TRACK TO COMPLETE ENROLLMENT IN FIRST HALF OF 2023
    * LONGBOARD PHARMACEUTICALS INC - LP352 PHASE 1B/2A PACIFIC
STUDY
TOPLINE DATA EXPECTED IN SECOND HALF OF 2023
    * LONGBOARD PHARMACEUTICALS INC SAYS AT DECEMBER 31,
LONGBOARD'S
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE
APPROXIMATELY $67.6 MILLION
    * LONGBOARD PHARMACEUTICALS INC - LP659 PHASE 1 INITIATION
OF
FIRST IN-HUMAN CLINICAL STUDY ON TRACK FOR FIRST HALF OF 2023
    * LONGBOARD PHARMACEUTICALS INC - ENDED 2022 WITH $67.6
MILLION IN
CASH, CASH EQUIVALENTS AND INVESTMENTS
    * LONGBOARD PHARMACEUTICALS INC - CASH RUNWAY IS EXPECTED TO
SUPPORT OPERATIONS INTO MID-2024

Source text for Eikon:  ID:nBw1V2RQJa 
Further company coverage:  LBPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))